News

WuXi News

Filter By

2020/06/01

WuXi AppTec Appoints Dr. David Chang as CEO of WuXi Advanced Therapies Business Unit

SHANGHAI and PHILADELPHIA, June 1, 2020 -- WuXi AppTec, a leading global pharmaceutical and medical device open-access capability and technology platform company, announced today the appointment of Dr. David Chang as Chief Executive Officer of WuXi Advanced Therapies business unit (WuXi ATU), WuXi AppTec’s cell and gene therapy Contract Development and Manufacturing Organization (CDMO). In this new executive role, Dr. Chang will provide strategic, scientific and operational leadership to the company’s global cell and gene therapy R&D and manufacturing services.

Read more

2020/05/18

WuXi Advanced Therapies Launches New Closed Process CAR-T Cell Therapy Platform

May 18, 2020 – Philadelphia, PA - WuXi Advanced Therapies, a leading global Contract Development and Manufacturing Organization (CDMO) offering end-to-end contract services for the advanced therapies industry, announced today the expansion of its service capabilities to offer a fully integrated Closed Process CAR-T Cell Therapy Platform. This new platform will accelerate the timeline for cell and gene therapy development, manufacturing and release while providing greater predictability.

Read more

2020/04/29

WuXi AppTec Reports Solid First-Quarter 2020 Results

SHANGHAI, April 29, 2020 /PRNewswire/ -- WuXi AppTec Co., Ltd. (stock code: 603259.SH / 2359.HK), a company that provides a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical, biotech and medical device industries worldwide to advance discoveries and deliver groundbreaking treatments to patients, announces its unaudited financial results for the First-Quarter 2020 ("Reporting Period").

Read more

2020/03/24

WuXi AppTec Reports Strong 2019 Annual Results

(SHANGHAI, March 24, 2020) — WuXi AppTec Co., Ltd. (stock code: 603259.SH / 2359.HK), a company that provides a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical, biotech and medical device industries worldwide to advance discoveries and deliver groundbreaking treatments to patients, announces its audited annual results for the year ended December 31, 2019 (“Reporting Period”).

Read more

2020/03/11

WuXi AppTec Wuhan Site Resumes Operation

SHANGHAI, March 11, 2020 – WuXi AppTec announced today that the company’s Wuhan site has resumed operations, in compliance with local regulations and global COVID-19 health and safety guidelines. Operations at the Wuhan facility, which provides discovery chemistry services, will ramp up over the coming days and weeks. With this site’s re-opening, WuXi AppTec has now resumed operations at all facilities in China. WuXi AppTec is taking every precaution to ensure the health and safety of its employees across every site.

Read more